Health/Biotechnology
Virtus KAR Health Sciences Fund
Last updated: 2026-09-03
The Verdict
Virtus KAR Health Sciences Fund charges an expense ratio of 1.40%. On a $100,000 portfolio, that's $1,400 per year in fees, and it scales with the amount invested. Supreme.PM's decoded model tracked it at 89% correlation, for a flat monthly subscription that does not change with portfolio size.
Expense Ratio
1.40%
Star Rating
2/ 5
Market Beta
1.04
Model Correlation
89%
Sharpe Ratio
-0.08
Max Drawdown
26.96%
Supreme.PM Cost
Flat monthly subscription
Not a percentage of your assets
Performance
Performance comparison — 1Y: Fund -0.8% vs Model 2.8%; 3Y: Fund -8.4% vs Model -1.8%; 5Y: Fund -9.7% vs Model -7.2%.
Alpha After Fees
Supreme.PM's model achieves 89% correlation with Virtus KAR Health Sciences Fund, providing similar exposure at a flat subscription cost.
Fee Analysis
Virtus KAR Health Sciences Fund charges 1.40% of assets annually. Supreme.PM charges a flat monthly subscription instead, so its cost does not rise as a portfolio grows.
Data sources: Refinitiv Lipper, SEC EDGAR Filings, Supreme.PM Analytics
Past performance does not guarantee future results. Model returns are backtested and may not reflect actual trading conditions.
Related
Health/Biotechnology Category
Browse all Health/Biotechnology funds
Health/Biotechnology Rankings
Top-rated Health/Biotechnology funds
Our Methodology
How we decode fund strategies
Fidelity Select Health Care Portfolio
4-star rated
Fidelity Select Biotechnology Portfolio
3-star rated
Fidelity Select Health Care Services Portfolio
1-star rated
Fidelity Advisor Health Care Fund
3-star rated
Rydex Biotechnology Fund
3-star rated
Frequently Asked Questions
What is the expense ratio of Virtus KAR Health Sciences Fund?
Virtus KAR Health Sciences Fund has an expense ratio of 1.40%, charged as a percentage of the amount invested. Supreme.PM's decoded model is offered for a flat monthly subscription instead.
How does Supreme.PM replicate Virtus KAR Health Sciences Fund?
Supreme.PM builds a transparent, rules-based model of listed securities designed to track this fund's return profile. Over the measured period it tracked the fund closely, at 89% correlation. The model is published in full, so its positions are visible rather than disclosed with a delay.
What are the risks of fund replication?
While our models aim for high correlation, they may not perfectly match the fund's returns due to timing differences in rebalancing, transaction costs, and disclosure delays. Backtested results may not reflect future performance.
Get This Strategy
Start investing with Supreme.PM's decoded model and save on fees while capturing similar returns.